Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Lozano, 2012, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2095, 10.1016/S0140-6736(12)61728-0 Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262 Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 2012, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016/j.jhep.2011.12.001 Gao, 2012, Risk factors of hepatocellular carcinoma--current status and perspectives, Asian Pac J Cancer Prev, 13, 743, 10.7314/APJCP.2012.13.3.743 Mazzaferro, 2014, Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation, Semin Liver Dis, 34, 415, 10.1055/s-0034-1394365 Lu, 2014, Recent advances in the prevention of hepatocellular carcinoma recurrence, Semin Liver Dis, 34, 427, 10.1055/s-0034-1394141 Bruix, 2015, Liver cancer: Approaching a personalized care, J Hepatol, 62, S144, 10.1016/j.jhep.2015.02.007 Bruix, 2014, Hepatocellular carcinoma: clinical frontiers and perspectives, Gut, 63, 844, 10.1136/gutjnl-2013-306627 Omata, 2010, Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma, Hepatol Int, 4, 439, 10.1007/s12072-010-9165-7 Verslype, 2012, Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, vii41, 10.1093/annonc/mds225 Kudo, 2011, Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version, Dig Dis, 29, 339, 10.1159/000327577 Zhuang, 2013, Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis, PLoS One, 8, e61361, 10.1371/journal.pone.0061361 Okita, 2015, Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study, J Gastroenterol, 50, 191, 10.1007/s00535-014-0956-9 Yoshida, 2011, Effect of vitamin K2 on the recurrence of hepatocellular carcinoma, Hepatology, 54, 532, 10.1002/hep.24430 Liu, 2009, Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage, J Hepatol, 50, 958, 10.1016/j.jhep.2008.12.023 Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Llovet, 2005, Resection and liver transplantation for hepatocellular carcinoma, Semin Liver Dis, 25, 181, 10.1055/s-2005-871198 Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443 Forner, 2008, Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology, 47, 97, 10.1002/hep.21966 Chan, 2008, Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies, Liver Transpl, 14, 956, 10.1002/lt.21449 Tung-Ping Poon, 2000, Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma, Ann Surg, 232, 10, 10.1097/00000658-200007000-00003 Schulz, 2010, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials, BMJ, 340, c332, 10.1136/bmj.c332 Colombo, 2014, Role of antiviral treatment for HCC prevention, Best Pract Res Clin Gastroenterol, 28, 771, 10.1016/j.bpg.2014.07.017 Hsu, 2015, Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma, Semin Oncol, 42, 329, 10.1053/j.seminoncol.2014.12.023 Bruix, 2012, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial, J Hepatol, 57, 821, 10.1016/j.jhep.2012.06.014 Bruix J, Cheng A-L, Meinhardt G, Nakajima K, DeSanctis Y, Llovet J. Retrospective pooled analysis of advanced HCC patients in SHARP and AP randomized clinical trials. International Liver Cancer Association annual meeting. Sept 4–6, 2015. Paris, France. 248. Iavarone, 2011, Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy, Hepatology, 54, 2055, 10.1002/hep.24644 Bolondi, 2015, Refining sorafenib therapy: lessons from clinical practice, Future Oncol, 11, 449, 10.2217/fon.14.261 Lencioni, 2014, GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis, Int J Clin Pract, 68, 609, 10.1111/ijcp.12352 Yang, 2011, The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets, Semin Cancer Biol, 21, 35, 10.1016/j.semcancer.2010.10.007 Welti, 2013, Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer, J Clin Invest, 123, 3190, 10.1172/JCI70212 Haas, 2015, Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial, Proc Am Soc Clin Oncol, 33